Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$189.66 USD
-0.58 (-0.30%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $189.87 +0.21 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
INSP 189.66 -0.58(-0.30%)
Will INSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSP
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
INSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Inspire (INSP) Might be Well Poised for a Surge
Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
Other News for INSP
Invesco Small Cap Growth Fund Q2 2024 Review
Invesco Main Street Small Cap Fund Q2 2024 Review
Commit To Purchase Inspire Medical Systems At $135, Earn 13.3% Using Options
Maintaining Hold on Inspire Medical Systems Amid Solid Q2 Performance and Cautious H2 Revenue Outlook
ClearBridge Global Growth Strategy Q2 2024 Commentary